Gelatin microspheres: Initial clinical experience for the transcatheter arterial embolization

Nitta, Norihisa; Ohta, Shin‐ichi; Tanaka, Toyohiko; Takazakura, Ryutaro; Nagatani, Yukihiro; Kono, Naoaki; Sonoda, Akinaga; Seko, A; Furukawa, Akira; Takahashi, Masashi; Murata, Kiyoshi; Tabata, Yasuhiko

doi:10.1016/j.ejrad.2007.07.021

Cited by 11 publications

(5 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In clinical studies, we verified the embolisation effects of GMSs alone and the effects of cisplatin-eluting GMSs on metastatic liver tumours [8,26]. Moreover, we found that cisplatineluting GMSs elicited milder adverse effects than systemic chemotherapy and the arterial infusion of other anticancer drugs.…”

Section: Discussionmentioning

confidence: 59%

A combination of cisplatin-eluting gelatin microspheres and flavopiridol enhances anti-tumour effects in a rabbit VX2 liver tumour model

Nitta¹,

Sonoda²,

Seko³

et al. 2010

BJR

View full text Add to dashboard Cite

ABSTRACT. The aim of this study was to investigate whether the combination of cisplatin-eluting gelatin microspheres (GMSs) and flavopiridol enhances anti-tumour effects in a rabbit VX2 liver tumour model. Tumour-bearing rabbits (n521) were divided into five groups and infused from the proper hepatic artery. Group 1 (n55) received cisplatin-eluting GMSs (1 mg kg ). On days 0 and 7 after procedures the liver tumour volume was measured using a horizontal open MRI system and the relative tumour volume growth rates for 7 days after treatment were calculated. On T 1 weighted images, the tumours were visualised as circular, lowintensity areas just below the liver surface. After treatment, the signals remained similar. The relative tumour volume growth rate for 7 days after treatment was 54.2¡22.4% in Group 1, 134.1¡40.1% in Group 2,166.7¡48.1% in Group 3, 341.8¡8.6% in Group 4 and 583.1¡46.9% in Group 5; the growth rate was significantly lower in Group 1 than the other groups (p,0.05). We concluded that in our rabbit model of liver tumours the combination of cisplatin-eluting GMSs and flavopiridol was effective.

show abstract

Section: Discussionmentioning

confidence: 59%

A combination of cisplatin-eluting gelatin microspheres and flavopiridol enhances anti-tumour effects in a rabbit VX2 liver tumour model

Nitta¹,

Sonoda²,

Seko³

et al. 2010

BJR

View full text Add to dashboard Cite

show abstract

“…Preliminary studies as well as the present study have revealed some of the characteristics of 131 I-DEM: (I) favorable arterial embolization, where the rigid GMs remain in the small arteries in the liver after infusion via the hepatic artery. As an alien protein, gelatin activates fibroblasts and macrophages in blood vessels and surrounding tissues, which gradually wrap around the microspheres and cause fibrillation and embolism of the vasculature, resulting in long-term blockage of the blood stream (30,31). (II) High intratumoral concentration: as indicated in our study, most microspheres are retained in the tumor rather than distributed all over the liver or extrahepatic tissues, achieving a targeted radiation effect.…”

Section: Discussionmentioning

confidence: 80%

131Iodine-DEM TACE vs. conventional TACE in cirrhotic patients with hepatocellular carcinoma: a single center experiment

Ma¹,

Duan²,

Li³

et al. 2021

J Gastrointest Oncol

View full text Add to dashboard Cite

Background: To evaluate the safety and efficacy of transcatheter arterial chemoembolization (TACE) with 131 iodine-doxorubicin-eluting gelatin microspheres ( 131 I-DEM TACE) compared with conventional TACE (cTACE) with polyvinyl alcohol foam (PVA) embolization microspheres. Methods: A total of 22 patients diagnosed with hepatocellular carcinoma were equally divided into 2 groups. The patients who underwent TACE with 131 I-DEM (25.7×10 7 Bq of 131iodine and 10 mg of doxorubicin) were compared to controls who received cTACE with PVA embolization microspheres. Therapeutic effects were evaluated by the tumor regression rates, levels of alpha-fetoprotein in serum, survival rates, and complications. Results: The operative complications of the 2 groups were not significantly different (P=0.753). The radioactivity ratio of the tumor to the liver was approximately 4.1:1 for the 131 I-DEM TACE group. In the 131 I-DEM TACE group, 54.5% of patients achieved tumor regression of more than 50%, compared to 36.6% of patients in the cTACE group. AFP levels in serum declined in 100% of patients in the 131 I-DEM TACE group and 50% of patients in the cTACE group. The median survival time of the patients was 12.0±3.3 months for the 131 I-DEM TACE group and 10.0±3.3 months for the cTACE group. There were no significant differences in survival between the 2 groups (P=0.414). Conclusions: 131I-DEM may become a potential radiochemoembolization agent to treat patients with unresectable hepatocellular carcinoma through TACE.

show abstract

“…1). [19][20][21] Finally, we demonstrate the utility of the obtained micro- In vitro enzymatic degradation. Degradation kinetics of GMPs was observed in a trypsin phosphate-buffered saline solution at 38 °C.…”

mentioning

confidence: 81%

“…In this study, we fabricate uniform gelatin emulsion precursors using a microfluidic technique and consecutively cross-link them by inbound diffusion of GA from the oil continuous phase to the suspending gelatin droplets, thereby inducing the formation of a microshell structure (Figure ). − Finally, we demonstrate the utility of the obtained microshell structures by employing them in the development of a new type of chemoembolic agents.…”

Section: Introductionmentioning

confidence: 94%

Monodisperse Microshell Structured Gelatin Microparticles for Temporary Chemoembolization

Kim¹,

Han²,

Choi³

et al. 2018

Biomacromolecules

View full text Add to dashboard Cite

Embolization is a nonsurgical, minimally invasive procedure that deliberately blocks a blood vessel. Although several embolic particles have been commercialized, their much wider applications have been hampered owing mainly to particle size variation and uncontrollable degradation kinetics. Herein we introduce a microfluidic approach to fabricate highly monodisperse gelatin microparticles (GMPs) with a microshell structure. For this purpose, we fabricate uniform gelatin emulsion precursors using a microfluidic technique and consecutively cross-link them by inbound diffusion of glutaraldehyde from the oil continuous phase to the suspending gelatin precursor droplets. A model micromechanic study, carried out in an artificial blood vessel, demonstrates that the extraordinary degradation kinetics of the GMPs, which stems from the microshell structure, enables controlled rupturing while exhibiting drug release under temporary chemoembolic conditions.

show abstract

Gelatin microspheres: Initial clinical experience for the transcatheter arterial embolization

Cited by 11 publications

References 14 publications

A combination of cisplatin-eluting gelatin microspheres and flavopiridol enhances anti-tumour effects in a rabbit VX2 liver tumour model

A combination of cisplatin-eluting gelatin microspheres and flavopiridol enhances anti-tumour effects in a rabbit VX2 liver tumour model

131Iodine-DEM TACE vs. conventional TACE in cirrhotic patients with hepatocellular carcinoma: a single center experiment

Monodisperse Microshell Structured Gelatin Microparticles for Temporary Chemoembolization

Contact Info

Product

Resources

About